Latest progress in molecular biology and treatment in genitourinary tumours

• A. González-del-Alba ^[1] ; J. Á. Arranz ^[9] ; J. Bellmunt ^[2] ; J. P. Maroto ^[10] ; O. Fernández-Calvo ^[11] ; B. P. Valderrama ^[3] ; E. González-Billalabeitia ^[12] ; M. J. Méndez-Vidal ^[4] ; J. Cassinello ^[5] ; N. Romero-Laorden ^[13] ; M. Á. Climent ^[6] ; J. Puente ^[7] ; I. Peláez ^[14] ; M. Lázaro-Quintela ^[15] ; E. Gallardo ^[16] ; C. Suárez ^[8]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Dana–Farber Cancer Institute

     Dana–Farber Cancer Institute

     City of Boston, Estados Unidos

     
  3. [3] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  4. [4] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  5. [5] Hospital Universitario de Guadalajara

     Hospital Universitario de Guadalajara

     Guadalajara, España

     
  6. [6] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  7. [7] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  8. [8] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  9. [9] Hospital Universitario Gregorio Marañón
  10. [10] Hospital Universitari Santa Creu i Sant Pau
  11. [11] Complexo Hospitalario Universitario de Ourense
  12. [12] Hospital Universitario Morales Meseguer
  13. [13] Hospital Universitario La Princesa
  14. [14] Hospital Universitario de Cabueñes
  15. [15] Hospital Universitario Alvaro Cunqueiro
  16. [16] Hospital Universitari Parc Tauli

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 12 (December), 2020, págs. 2175-2195
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered. Research in oncology moves quickly and new data of great relevance for clinical practice are communicated every year. For this reason, a group of experts, focused exclusively on the treatment of genitourinary tumours and who get together every year in the BestGU conference to assess the latest progress in this field have summarized the most important advances in a single review, along with a critical assessment of whether these results should alter daily clinical practice.